456,865 Shares in Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Purchased by M28 Capital Management LP

M28 Capital Management LP purchased a new stake in Atara Biotherapeutics, Inc. (NASDAQ:ATRAGet Rating) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 456,865 shares of the biotechnology company’s stock, valued at approximately $7,200,000. Atara Biotherapeutics accounts for about 5.6% of M28 Capital Management LP’s portfolio, making the stock its 9th biggest position.

A number of other hedge funds also recently modified their holdings of the business. Macquarie Group Ltd. increased its position in Atara Biotherapeutics by 326.1% during the 3rd quarter. Macquarie Group Ltd. now owns 3,311 shares of the biotechnology company’s stock worth $59,000 after buying an additional 2,534 shares during the period. Point72 Hong Kong Ltd increased its holdings in shares of Atara Biotherapeutics by 1,155.2% during the third quarter. Point72 Hong Kong Ltd now owns 7,845 shares of the biotechnology company’s stock worth $140,000 after purchasing an additional 7,220 shares during the period. LPL Financial LLC bought a new position in shares of Atara Biotherapeutics during the third quarter worth approximately $181,000. AlphaCrest Capital Management LLC bought a new stake in shares of Atara Biotherapeutics in the fourth quarter valued at approximately $189,000. Finally, Teacher Retirement System of Texas bought a new stake in shares of Atara Biotherapeutics in the third quarter valued at approximately $205,000.

Several equities analysts have weighed in on ATRA shares. Citigroup cut Atara Biotherapeutics from a “buy” rating to a “neutral” rating and dropped their price objective for the company from $15.00 to $8.00 in a report on Monday, May 9th. JPMorgan Chase & Co. dropped their price target on Atara Biotherapeutics from $27.00 to $22.00 and set an “overweight” rating for the company in a research note on Monday, March 28th. HC Wainwright reiterated a “buy” rating and set a $31.00 price objective on shares of Atara Biotherapeutics in a research note on Thursday, January 27th. StockNews.com cut shares of Atara Biotherapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday. Finally, Canaccord Genuity Group reduced their price target on shares of Atara Biotherapeutics from $78.00 to $67.00 in a research report on Tuesday, March 1st. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, Atara Biotherapeutics currently has a consensus rating of “Hold” and a consensus target price of $30.43.

Shares of ATRA stock traded up $0.29 during mid-day trading on Tuesday, reaching $5.59. 1,298,878 shares of the stock traded hands, compared to its average volume of 1,004,791. The company has a market cap of $522.14 million, a price-to-earnings ratio of -1.54 and a beta of 1.92. The stock’s fifty day simple moving average is $8.08 and its two-hundred day simple moving average is $12.97. Atara Biotherapeutics, Inc. has a 1-year low of $4.84 and a 1-year high of $20.04.

Atara Biotherapeutics (NASDAQ:ATRAGet Rating) last posted its earnings results on Thursday, May 5th. The biotechnology company reported ($0.87) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.98) by $0.11. Atara Biotherapeutics had a negative net margin of 1,451.79% and a negative return on equity of 113.94%. During the same quarter last year, the business posted ($0.86) EPS. Equities research analysts expect that Atara Biotherapeutics, Inc. will post -3.45 EPS for the current fiscal year.

About Atara Biotherapeutics (Get Rating)

Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma.

Featured Stories

Want to see what other hedge funds are holding ATRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Atara Biotherapeutics, Inc. (NASDAQ:ATRAGet Rating).

Institutional Ownership by Quarter for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.